Federal Register of Legislation - Australian Government

Primary content

This instrument is a notification that the Minister's delegate has exercised discretion under subsection 99ACF(3AA) of the National Health Act 1953 to not apply a first new brand statutory price reduction that would otherwise apply to the specified drugs on 1 April 2020.
Administered by: Health
Registered 31 Mar 2020

 

 

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 99ACF(3AA) of the National Health Act 1953.

Dated       30  March 2020

 

 

 

 

 

 

 

 

 

THEA DANIEL

 

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

 

 

 

 

 

 

 

1              Name of Determination

                This instrument is the National Health (April 2020 First New Brand statutory price reduction) (Exercise of Ministerial discretion) Determination 2020.  

2              Commencement

                This instrument commences on 1 April 2020.

3              Definition

 

              Note: A number of expressions used in this instrument are defined in Part VII the Act,

 

In this instrument:

  

   Act means the National Health Act 1953.

4              Authority

 

This instrument is made under subsection 99ACF(3AA) of the Act.

5              Brand of pharmaceutical item not subject to a price reduction

 

                I determine under subsection 99ACF(3AA) of the Act that, for the purposes of subsection 99ACF(2AB), the approved ex-manufacturer price that comes into force on 1 April 2020 of each brand of pharmaceutical item specified in column 2 as an item in the table in Schedule 1 is to be worked out using a reduction of zero %.

 

 

 


Schedule 1 Brands of pharmaceutical items with approved ex-manufacturer price not reduced

 

Column 1

Column 2

Item

Brand of Pharmaceutical Item

 

Drug

Form

Manner of administration

Brand

1

Levodopa with carbidopa

Tablet (modified release) 200 mg-50 mg (as monohydrate)

Oral

Sinemet CR

 

2

Levodopa with carbidopa

Tablet (prolonged release) 200 mg-50 mg

Oral

Sinemet CR Prolonged-Release Tablets